Menu
Search Clinical Trials
Back to Search Results
Study Complete
Astellas Study ID
8062-CL-0101

A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects with Fibromyalgia

Astellas Study ID
8062-CL-0101
Clinicaltrials.gov ID
NCT03092726
EUCTIS ID
N/A
EudraCT ID
N/A
jRCT ID
N/A
CN CDE ID
N/A
Get more information

Study summary

The purpose of this study was to assess analgesic efficacy of ASP8062 relative to placebo as well as the safety and tolerability. This study also assessed the treatment differences in physical function as well the improvements in overall subject status (e.g., fibromyalgia symptoms, global functioning) of ASP8062 relative to placebo.

Additional Study Details

Phase
2
Product
N/A
Product
ASP8062
Placebo
Type
Interventional
Masking
Double (Participant, Investigator)
Enrollment number
183
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Download Document(s)
Plain Language Summary
Available Language(s): English
Download Document(s)
Protocol
Available Language(s): English
Download Document(s)
Statistical Analysis Plan (SAP)
Available Language(s): English
Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects with Fibromyalgia? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Summit Research Network
    Portland, OREGON, United States, 97210
    Contact Us
    Completed
    Omega Medical Research
    Warwick, RI, United States, 02886
    Contact Us
    Completed
    Collaborative Neuroscience Network, LLC.
    Torrance, CA, United States, 90502
    Contact Us
    Completed
    The Center For Pharmaceutical Research
    Kansas City, MO, United States, 64114
    Contact Us
    Completed
    Meridian Clinical Research
    Dakota Dunes, SD, United States, 57049
    Contact Us
    Completed
    Chicago Research Center, Inc
    Chicago, IL, United States, 60634
    Contact Us
    Completed
    ClinSearch, LLC
    Chattanooga, TN, United States, 37421
    Contact Us
    Completed
    Medisphere Medical Research Center, LLC
    Evansville, IN, United States, 47714
    Contact Us
    Completed
    Elite Clinical Research, LLC
    Jackson, MS, United States, 39202
    Contact Us
    Completed
    Infinity Medical Research, Inc
    North Dartmouth, MA, United States, 02747
    Contact Us
    Completed
    University of Cincinnati
    Cincinnati, OH, United States, 45219
    Contact Us
    Completed
    PAB Clinical Research
    Brandon, FL, United States, 33511
    Contact Us
    Completed
    Private Practice
    Raleigh, NC, United States, 27609
    Contact Us
    Completed
    Neuro-Behavioral Clinical Research, Inc
    Canton, OH, United States, 44718
    Contact Us
    Completed
    Avail Clinical Research, LLC
    Deland, FL, United States, 32720
    Contact Us
    Completed
    PMG of Winston-Salem, LLC
    Winston-Salem, NC, United States, 27103
    Contact Us
    Completed
    Lehigh Center for Clinical Research
    Allentown, PA, United States, 18104
    Contact Us
    Completed
    Neurobehavioral Research, Inc
    Cedarhurst, NY, United States, 11516
    Contact Us
    Withdrawn
    Associated Neurologists of Southern Connecticut, PC
    Fairfield, CT, United States, 06824
    Contact Us
    Completed
    NY Scientific
    Brooklyn, NY, United States, 11235
    Contact Us
    Completed
    Clinical Investigation Specialists, Inc
    Kenosha, WI, United States, 53142
    Contact Us
    Completed
    Clinical Neuroscience Solutions, Inc
    Orlando, FL, United States, 32801
    Contact Us
    Completed
    Noesis Pharma, LLC
    Phoenix, AZ, United States, 85032
    Contact Us
    Completed
    Advanced Biomedical Research of America
    Las Vegas, NV, United States, 89123
    Contact Us
    Completed
    Excell Research, Inc
    Oceanside, CA, United States, 92056
    Contact Us
    Trial info
    Follow Trial
    Age
    18 - 80 years
    Diamond icon
    Condition
  • Fibromyalgia
    • Gender icon
    Sex
    Female & Male
    Calendar icon
    Trial Dates
    May 2017 - Mar 2018
    Additional Study Details
    Inclusion Criteria
    • Subject has a body mass index (BMI) ≤ 45 kg/m^2.
    • Female subject must either:
      • Be of nonchildbearing potential:
      • Postmenopausal (defined as at least 1 year without any menses) prior to Screening, or,
      • Documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
      • Or, if of childbearing potential, agree not to try to become pregnant during the study and for 28 days after the final study drug administration, have a negative blood pregnancy test at Screening and negative urine test on Day 1, and if heterosexually active, agree to consistently use 1 form of highly effective birth control starting at Screening and throughout the study period and for 28 days after the final study drug administration.
    • Female subject must agree not to breastfeed at Screening and throughout the study period, and for 28 days after the final study drug administration.
    • Female subject must not donate ova starting at Screening, throughout the study period, and for 28 days after the final study drug administration.
    • Male subject must not donate sperm starting at Screening and throughout the study period, and for 90 days after the final study drug administration.
    • A sexually active male subject with female partner(s) who are of childbearing potential is eligible if:
      • Agree to use a male condom starting at screening and continue throughout study treatment and for 90 days after the final study drug administration. If the male subject has not had a vasectomy or is not sterile the male subjects female partner(s) is utilizing 1 form of highly effective birth control starting at screening and continue throughout study treatment, and for 90 days after the male subject receives final study drug administration.
    • Male subject with a partner of child-bearing potential, or a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom throughout the study period and for 90 days after the final study drug administration.
    • Subject meets the American College of Rheumatology (ACR) 1990 fibromyalgia diagnostic criteria at Screening:
      • Widespread pain for at least 3 months, defined as the presence of all of the following: Pain above and below the waist and pain in the axial skeleton (cervical spine or anterior chest or thoracic spine or low back) must be present.
      • Pain in at least 11 of 18 tender point sites on digital palpation. Digital palpation should be performed with an approximate force of 4 kg.
    • Subject meets the ACR 2010 fibromyalgia diagnostic criteria at Screening:
      • Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5 or WPI 3-6 and SS scale score ≥ 9.
      • Symptoms have been present at a similar level for at least 3 months.
      • The subject does not have a disorder that would otherwise explain the pain.
    • Subject has a pain score ≥ 4 on the revised fibromyalgia impact questionnaire (FIQR) pain item at Screening.
    • Subject is compliant with daily pain recordings during the Baseline Diary Run-In period, as defined by the completion of a minimum of 5 of 7 daily average pain ratings and agrees to complete daily diaries throughout the duration of the study.
    • Subject has a mean daily average pain score ≥ 4 and ≤ 9 on an 11-point 0 to 10 NRS as recorded in the subject e-diary during the Baseline Diary Run-In period, and meeting pre-specified criteria for daily average pain scores.
    • Subject agrees to use only acetaminophen as rescue medication for fibromyalgia pain throughout the course of the trial (up to 1000 mg per dose and not to exceed 3000 mg/day).
    • Subject agrees not to initiate or change any non-pharmacologic interventions (including normal daily exercise routines, chiropractic care, physical therapy, psychotherapy, and massage therapy) during the course of the study. Non-pharmacologic interventions must be stable for a minimum of 30 days prior to Screening. And subject agrees to maintain usual level of activity for the duration of the study.
    • Subject is capable of completing study assessments and procedures.
    • Subject agrees not to participate in another interventional study from Screening through the End of Study (EOS) visit.
    MaximizeExclusion Criteria
    • Subject has received an investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to Screening.
    • Subject has had no meaningful improvement from 2 or more prior treatments (commercially available) for fibromyalgia (in at least 2 pharmacologic classes).
    • Subject has had known hypersensitivity or intolerance to the use of acetaminophen or associated formulation components; known hypersensitivity to the formulation components of ASP8062.
    • Subject has pain due to diabetic peripheral neuropathy, post-herpetic neuralgia, traumatic injury, prior surgery, complex regional pain syndrome, or other source of pain that would confound or interfere with the assessment of the subject’s fibromyalgia pain or require excluded therapies during the subject’s study participation.
    • Subject has infectious or inflammatory arthritis (for example, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, gout), autoimmune disease (for example, systemic lupus erythematosus), or other widespread rheumatic disease other than fibromyalgia.
    • Subject has a current, untreated moderate or severe major depressive disorder as assessed by the Mini-International Neuropsychiatric Interview (M.I.N.I.). Subject with current, treated major depressive disorder can be included provided that it is without clinically significant changes in symptoms while on the same dose of a protocol allowed antidepressant for greater than 60 days prior to Screening.
    • Subject has initiated any non-pharmacologic interventions for the treatment of fibromyalgia or depression within 30 days prior to Screening or during the Screening period.
    • Subject has a history of any psychotic and/or bipolar disorder as assessed by the M.I.N.I.
    • Subject has a Hospital Anxiety and Depression Scale (HADS) score > 14 on the Depression subscale at Screening or at the time of Visit 3 (Randomization).
    • Subject has a history of suicide attempt or suicidal behavior within the last 12 months, or has suicidal ideation within the last 12 months (a response of “yes” to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale C-SSRS]), or who is at significant risk to commit suicide at Screening and at the time of Visit 3 (Randomization).
    • Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis, or a serum creatinine > 1.5 x the ULN at Screening. These assessments may be repeated once, after a reasonable time period (but within the Screening period).
    • Subject has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 1.5 times the upper limit of the reference range at Screening. These assessments may be repeated once, after a reasonable time period (but within the Screening period).
    • Subject has a positive test for hepatitis B surface antigen (HBsAg), hepatitis A virus antibodies (immunoglobulin M) (anti-HAV [IgM]) or hepatitis C virus antibodies (anti-HCV) at Screening or has history of a positive test for human immunodeficiency virus type 1(HIV-1) and/or type 2 (HIV-2).
    • Subject has a resting systolic blood pressure > 180 mmHg or < 90 mmHg, and/or a sitting diastolic blood pressure > 100 mmHg at Screening. These assessments may be repeated once, after a reasonable time period (but within the Screening period).
    • Subject has a clinically significant abnormality on 12-lead electrocardiogram (ECG) at Screening or Visit 3 (Randomization). If the ECG is abnormal an additional ECG can be carried out. If this also gives an abnormal result, the subject must be excluded.
    • Subject has a history of myocardial infarction (within 6 months of Screening), unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsade de pointes, structural heart disease or a family history of Long QT Syndrome.
    • Subject has evidence of any clinically significant, uncontrolled cardiovascular, gastrointestinal, endocrinologic (low thyroid stimulating hormone [TSH], but euthyroid is allowed), hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary (including obstructive sleep apnea not controlled by a continuous positive airway pressure device) neurologic, dermatologic, psychiatric, renal and/or other major disease (exclusive of fibromyalgia).
    • Subject has planned surgery during the study participation.
    • Subject has an active malignancy or a history of malignancy (except for treated nonmelanoma skin cancer) within 5 years of Screening.
    • Subject has a positive drug or alcohol test at Screening, Baseline Diary Run-In or prior to Randomization. However, a positive test for tetrahydrocannabinol (THC) and/or opioids is allowed at the Screening visit, but must be confirmed negative prior to Baseline Diary Run-In and Randomization.
    • Subject has a current or recent (within 12 months of Screening) history of a substance use disorder including cannabinoid and/or alcohol abuse disorder. Subject has used opioids for pain for more than 4 days during the week preceding the Screening visit.
    • Subject is currently using protocol specified prohibited medications and is unable to wash-out including over-the-counter (OTC) products and grapefruit and/or grapefruit juice.
    • Subject has filed or is awaiting judgment on a disability claim or has any pending worker’s compensation litigation or related monetary settlements.
    • Subject has any condition which makes the subject unsuitable for study participation.
    • Subject is an employee of the Astellas Group, the Contract Research Organization (CRO) involved, or the investigator site personnel directly affiliated with this study and/or immediate families (spouse, parent, child, or sibling, whether biological or legally adopted).

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    Find a Trial
    2

    Why are Clinical Trials Important?

    Learn More
    3

    Why Participate in a Clinical Trial?

    Discover More